Genscript Biotech 관리
관리 기준 확인 1/4
Genscript Biotech CEO는 Weihui Shao, Jul2021 에 임명되었습니다 의 임기는 3.33 년입니다. 총 연간 보상은 $ 2.48M, 14.3% 로 구성됩니다. 14.3% 급여 및 85.7% 보너스(회사 주식 및 옵션 포함). 는 HK$ 7.65M 가치에 해당하는 회사 주식의 0.034% 직접 소유합니다. 7.65M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 1.7 년입니다.
주요 정보
Weihui Shao
최고 경영자
US$2.5m
총 보상
| CEO 급여 비율 | 14.3% |
| CEO 임기 | 3.3yrs |
| CEO 소유권 | 0.03% |
| 경영진 평균 재임 기간 | 3.6yrs |
| 이사회 평균 재임 기간 | 1.7yrs |
최근 관리 업데이트
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
보상 대 시장: Weihui 의 총 보상 ($USD 2.48M )은 Hong Kong 시장( $USD 481.50K ).
보상과 수익: Weihui 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Weihui Shao (44 yo)
3.3yrs
테뉴어
US$2,477,000
보상
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| CEO & COO | 3.3yrs | US$2.48m | 0.034% HK$ 7.7m | |
| Co-Founder | 22.8yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | no data | 데이터 없음 | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 1.9yrs | US$531.00k | 데이터 없음 | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Chief Financial Officer | 3.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Marketing Officer for GenScript Life Science Group | no data | 데이터 없음 | 데이터 없음 |
3.6yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: 1548 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| Co-Founder | 9.5yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | 9.5yrs | 데이터 없음 | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 2.5yrs | US$531.00k | 데이터 없음 | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Member of Advisory Board | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
1.7yrs
평균 재임 기간
61.5yo
평균 연령
경험이 풍부한 이사회: 1548 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.